ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1465

Adherence To The Recommended Dosing Regimen Of Abatacept In The Real-World Setting In The Action Study: Is There a Dose-Creep In Overweight Patients?

H Nüßlein1, R Alten2, M Galeazzi3, H M Lorenz4, D Boumpas5, M T Nurmohamed6, W G Bensen7, Gerd Burmester8, H-H Peter9, F Rainer10, K Pavelka11, M Chartier12, C Poncet13, C Rauch14 and M Le Bars15, 1University Erlangen, Nürnberg, Germany, 2Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 3University of Siena, Siena, Italy, 4University Hospital Heidelberg, Heidelberg, Germany, 5Panepistimio Kritis, Rethymnon, Greece, 6VU University Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands, 7St. Joseph's Hospital/McMaster University, Hamilton, ON, Canada, 8Charité-Universitätsmedizin, Berlin, Germany, 9University of Freiburg, Freiburg, Germany, 10Hospital Barmherzige Brueder, Graz, Austria, 11Institute of Rheumatology, Prague, Czech Republic, 12Chiltern International, Neuilly, France, 13Docs International, Nanterre, France, 14Bristol-Myers Squibb, Munich, Germany, 15Bristol-Myers Squibb, Rueil-Malmaison, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Abatacept

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Reduced efficacy for achieving DAS28 <2.6 has been observed for anti-TNF agents in obese patients following 12 months of therapy. The odds ratio (95% confidence interval) was 2.43 (1.21, 4.88; p=0.01) with initial body mass index [BMI] 20–30 kg/m2 versus >30 kg/m2,1 which in theory could induce dose increases to maintain efficacy. Here we explore adherence to abatacept over 6 months in patients categorized according to BMI. Methods: ACTION is an ongoing, 2-year, international, non-interventional, prospective cohort of patients with RA treated with IV abatacept. All patients on abatacept treatment for ≥6 months, and with data available for infusion (at initiation and at 6 months) and BMI (at initiation), were considered in this analysis. BMI calculated at abatacept initiation categorized patients into normal (<25 kg/m2), overweight (25–<30 kg/m2) or obese (≥30 kg/m2) subgroups. Within each BMI category, adherence to treatment was assessed in patients who received appropriate dosage by body weight at initiation. Increase in dose and frequency of administration was assessed over 6 months. Results: An even distribution of patients was observed across the BMI subgroups at abatacept initiation in the overall population (<25 kg/m2: 399/1048 [38.1%]; 25–<30 kg/m2: 363/1048 [34.6%]; ≥30 kg/m2: 286/1048 [27.3%]). Baseline disease characteristics were similar across BMI subgroups, except auto-antibody status, with fewer obese seropositive patients: rheumatoid factor-positive, <25 kg/m2: 228/315 (72.4%); 25–<30 kg/m2: 220/293 (75.1%); ≥30 kg/m2: 132/232 (56.9%); anti-cyclic citrullinated peptide-positive, <25 kg/m2: 152/213 (71.4%); 25–<30 kg/m2: 138/204 (67.6%); ≥30 kg/m2: 87/153 (56.9%). Overall, 737/1048 (70.3%) patients with BMI data available received abatacept for ≥6 months and had infusion data available at initiation and at 6 months. A large proportion of patients received appropriate dosage regardless of BMI: at initiation (<25 kg/m2: 236/290 [81.4%]; 25–<30 kg/m2: 224/245 [92.2%]; ≥30 kg/m2: 182/202 [91.0%]). Adherence over 6 months in patients receiving appropriate dosage at initiation is presented in the table.

  <25 kg/m2 (n=236) 25–<30 kg/m2 (n=224) ≥30 kg/m2 (n=182)
Appropriate dosage at 6 months* 203/215 (94.4%) 197/200 (98.5%) 154/161 (95.7%)
Dose increase over 6 months* 11/215 (5.1%) 2/200 (1.0%) 4/161 (2.5%)
7–9 infusions received** 203/236 (86.0%) 199/224 (88.8%) 150/182 (82.4%)
1 additional infusion received 6/236 (2.5%) 3/224 (1.3%) 2/182 (1.1%)
Increase in dose or in frequency 17/236 (7.2%) 5/224 (2.2%) 6/182 (3.3%)
*Some patients had missing data for dose reported at 6 months; **Corresponding to a ratio of actual to recommended infusions within range of 80–120%
No patient received more than 1 additional infusion. No patient had both a dose increase and an increase in frequency of administration over 6 months. Conclusion: Analysis of adherence to the recommended dosing regimen of IV abatacept in the ACTION study showed that a large proportion of patients had good adherence at initiation, regardless of BMI. Few patients had an increase in dosage or frequency of administration over 6 months and nobody had both. Overall, there was no evidence for dose creep in overweight and obese patients treated with IV abatacept over 6 months in routine clinical practice. 1. Gremese E, et al. Arthritis Care Res 2013;65:94–100.

Disclosure:

H. Nüßlein,

Bristol-Myers Squibb, Abbott, Chugai, UCB, Essex, Wyeth, Pfizer, MSD, Novartis and Roche,

5,

Bristol-Myers Squibb, Abbott, Chugai, UCB, Essex, Wyeth, Pfizer, MSD, Novartis and Roche,

8;

R. Alten,

Bristol-Myers Squibb,

2,

Bristol-Myers Squibb,

9;

M. Galeazzi,
None;

H. M. Lorenz,

Abbvie, Pfizer, MSD, Roche, GlaxoSmithKline, Bristol-Myers Squibb,

5;

D. Boumpas,
None;

M. T. Nurmohamed,

BMS, MSD, Roche, Abbott, Pfizer and UCB,

2,

BMS, MSD, Roche, Abbott, Pfizer and UCB,

5,

BMS, MSD, Roche, Abbott, Pfizer and UCB,

8;

W. G. Bensen,

Abbott, Amgen, BMS, Janssen, Merck , Lilly , Novartis, Pfizer, Proctor and Gamble, Roche, sanofi -aventis, Schering, Takeda, UCB, Warner Chilcott, Wyeth,

2,

Abbott, Amgen, BMS, Janssen, Merck , Lilly , Novartis, Pfizer, Proctor and Gamble, Roche, sanofi -aventis, Schering, Takeda, UCB, Warner Chilcott, Wyeth,

5,

Abbott, Amgen, BMS, Janssen, Merck , Lilly , Novartis, Pfizer, Proctor and Gamble, Roche, sanofi -aventis, Schering, Takeda, UCB, Warner Chilcott, Wyeth,

8;

G. Burmester,

AbbVie, BMS, Pfizer, Roche, UCB,

2,

AbbVie, BMS, MSD, Pfizer, Roche, UCB,

5,

AbbVie, BMS, MSD, Pfizer, Roche, UCB,

8;

H. H. Peter,
None;

F. Rainer,
None;

K. Pavelka,

MSD, Pfizer, Amgen, AbbVie, Roche,

2,

MSD, Pfizer, Amgen, AbbVie, Roche,

5;

M. Chartier,

Bristol-Myers Squibb,

5;

C. Poncet,

Bristol-Myers Squibb,

5;

C. Rauch,

Bristol-Myers Squibb,

3;

M. Le Bars,

Bristol-Myers Squibb,

1,

Bristol-Myers Squibb,

3.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adherence-to-the-recommended-dosing-regimen-of-abatacept-in-the-real-world-setting-in-the-action-study-is-there-a-dose-creep-in-overweight-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology